VivoSeq
Nephrology

De Novo Renal Transplantation

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

De Novo Renal Transplantation is an early-stage landscape with 0 programs across 3 companies. The most active players are Aurinia Pharmaceuticals, Roche, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed6 · 75%
Terminated1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation
Completed·—·Phase 4·NCT03968588·108 enrolled
A Dose Escalation Study in de Novo Renal Transplantation
Completed·IITB-Med LLC·Phase 2·NCT04311632·13 enrolled
Study of ISA247 (Voclosporin) in De Novo Renal Transplantation
Completed·Aurinia Pharmaceuticals logoAurinia Pharmaceuticals·Phase 2·NCT00270634·334 enrolled
Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation
Completed·PProf. Dr. Petra Reinke·N/A·NCT02540395·184 enrolled
Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study
Completed·UUniversity Hospital, Ghent·Phase 4·NCT00895206·128 enrolled
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
Completed·Novartis logoNovartis·Phase 1/2·NCT02217410·59 enrolled
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
Terminated·IITB-Med LLC·Phase 2·NCT06365437·33 enrolled
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
Withdrawn·Roche logoRoche·Phase 2/3·NCT00729768

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)